BioNote, Inc (377740) Fair Value & Analysis
Healthcare · KR · Market cap 493B KRW
Fair value as of: Jun 24, 2026
Analysis
BioNote, Inc (377740) currently trades at 4,375 KRW, while our model-based Fair Value estimate is 3,245 KRW — implying the stock looks roughly 25.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents. In addition, it engages in the production and sell of medical devices. BioNote, Inc. was founded in 2003 and is headquartered in Hwaseong-si, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is BioNote, Inc (377740) undervalued?
What is the fair value of 377740?
What is the quality score of 377740?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.